Biomarkers of systemic inflammation, hemodynamic stress, degradation of the extracellular matrix and adverse left ventricular remodelling in primary anterior STEMI patients
Not changes in heart failure therapy but patient characteristics at admission predict unsuccessful guidance of therapy to a target of more than 30% NT-proBNP reduction
The diagnostic and economic implications of using a plasma nt-probnp of 300 or 400ng/litre as the threshold for ruling out the diagnosis of heart failure in a non selected british population